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The heterodimeric cytokine IL-12 plays a key 
role in host defense against intracellular mi-
crobes by inducing NK cell IFN-γ produc-
tion and by favoring the diff  erentiation  of 
IFN-γ–secreting CD4+ Th1 cells (1). IL-12 
has also been implicated in chronic infl  amma-
tory disorders characterized by excessive Th1 
responses. Recently, IL-23 was identifi  ed as a 
new member of the IL-12 cytokine family se-
creted by activated DCs and macrophages (2). 
Because of the shared p40 subunit between 
IL-12 (p40/p35) and IL-23 (p40/p19), early 
experiments that used anti-p40 mAb to neu-
tralize IL-12 in vivo have had to be reevalu-
ated. With the use of new tools, including 
p19-defi  cient mice, several autoimmune and 
chronic infl  ammatory diseases previously be-
lieved to be caused by IL-12 and Th1 responses 
have now indeed been shown to depend on 
IL-23, and not IL-12. Among such diseases are 
experimental autoimmune encephalomyelitis 
(EAE) that aff  ects the central nervous system 
(3, 4) and collagen-induced arthritis (CIA) of 
the joints (5).
The precise mechanism(s) by which IL-23 
contributes to infl   ammation is currently un-
known. The IL-23 receptor, which is com-
posed of IL-12Rβ1 combined with the IL-23R 
subunit (6), is expressed on activated and mem-
ory T cells, NK cells, DCs, and infl  ammatory 
macrophages and microglia (2, 3, 6). IL-23 was 
originally described to induce the proliferation 
and secretion of IL-17 (IL-17A)/IL-17F by 
CD4+ T cells with an activated or memory 
phenotype (2, 7), and such IL-23–driven IL-17+ 
CD4+ T cells were subsequently shown to be 
highly potent inducers of immune pathology 
in EAE (4). Recent studies have established 
that IL-17+ CD4+ T cells represent a novel 
subset of Th cells (Th17 cells) that in addition to 
IL-17/IL-17F also produces IL-6 and TNF-α 
(4, 8, 9). Binding of IL-17 and/or IL-17F to 
receptors on myeloid and endothelial cells pro-
motes the expression of IL-1, IL-6, IL-8, TNF, 
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tract that is caused in part by a dysregulated immune response to the intestinal fl  ora. The 
common interleukin (IL)-12/IL-23p40 subunit is thought to be critical for the pathogenesis 
of IBD. We have analyzed the role of IL-12 versus IL-23 in two models of Helicobacter 
hepaticus–triggered T cell–dependent colitis, one involving anti–IL-10R monoclonal anti-
body treatment of infected T cell–suffi  cient hosts, and the other involving CD4+ T cell 
transfer into infected Rag–/– recipients. Our data demonstrate that IL-23 and not IL-12 
is essential for the development of maximal intestinal disease. Although IL-23 has been 
implicated in the differentiation of IL-17–producing CD4+ T cells that alone are suffi  cient 
to induce autoimmune tissue reactivity, our results instead support a model in which IL-23 
drives both interferon 𝗄 and IL-17 responses that together synergize to trigger severe 
intestinal infl  ammation.
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and chemokines that are involved in mobilizing neutrophils 
and in driving chronic infl  ammation (3, 10).
Infl  ammatory bowel disease (IBD), comprising Crohn’s 
disease and ulcerative colitis, is a chronic infl  ammatory disor-
der of the gastrointestinal tract that is caused in part by a dys-
regulated immune response to the intestinal fl  ora. Levels of 
IL-12 and IL-23 have been shown to be increased in in-
fl  amed intestinal tissues (11–14), and anti-p40 mAb treatment 
has proven benefi  cial in Crohn’s disease as well as in experi-
mental models of intestinal infl  ammation (15–19). However, 
little information is currently available on the relative contri-
bution of IL-12 versus IL-23 in IBD pathogenesis.
We previously established a new model of bacterial-
  induced colitis involving infection of specifi  c pathogen-free 
IL-10–/– mice with Helicobacter hepaticus (20, 21). The disease that 
develops in H. hepaticus–infected (Hh+) IL-10–/– animals is as-
sociated with a Th1 response to the bacterium, and treatment 
from the start of the infection with anti-p40 mAb abrogates 
the development of intestinal infl   ammation (20). Further-
more, mice rendered double defi  cient for both IL-10 and p40 
are resistant to H. hepaticus–induced colitis, together demon-
strating a crucial role for p40 in disease pathogenesis (21).
In this study, we have investigated the role of IL-12 ver-
sus IL-23 in two bacterially driven T cell–dependent colitis 
models. Using a novel model of colitis involving anti–IL-
10R treatment of Hh+ WT mice, as well as our previously 
established H. hepaticus CD4 T cell adoptive transfer model 
(22), we demonstrate that IL-23 and not IL-12 is essential 
to trigger intestinal infl  ammation. Unexpectedly, although 
IL-23 has been implicated in the induction of pathogenic 
IL-17–producing T cells in EAE (4), in our model IL-17 in 
the absence of IFN-γ does not appear to be suffi   cient to in-
duce maximal colitis. Instead, our results support a model in 
which maximal intestinal infl  ammation depends on the func-
tion of both IFN-γ and IL-17.
RESULTS
Anti–IL-10R treatment leads to severe intestinal 
infl  ammation in Hh+ WT and IL-12p35–/– mice
Using a T cell transfer model of colitis triggered by adoptive 
transfer of CD4+ T cells into Hh+ Rag–/– recipients, we 
previously described the appearance of disease-protective 
CD4+ IL-10–secreting T regulatory cells after H. hepaticus 
infection of WT animals (22). Here we demonstrate that the 
CD4-mediated T regulatory cell mechanism revealed in the  Figure 1.  H. hepaticus infection plus anti–IL-10R mAb treatment 
leads to severe typhlocolitis in WT and p35–/– mice but reduced 
infl  ammation in the ascending colon of IFN-𝗄–/– animals. B6 WT, 
p40–/–, p35–/–, IFN-γ–/–, and B10 IL-10–/– mice were infected with H. hepaticus 
and treated with control or anti–IL-10R mAb once a week for 4 wk. 
Uninfected mice were included as controls. 1 wk after the last mAb 
  administration, pathology was analyzed in the cecum (A) and ascending 
colon (B). MLN cells were cultured with 5 μg/ml SHelAg, and IFN-γ (C) 
and IL-17 (D) were measured in 72-h supernatants. No IFN-γ or IL-17 was 
detected from cells cultured in medium alone. Data in A and B are pooled 
from two separate experiments and show histology scores from individual 
mice, with the horizontal line indicating the average for each group. Bars 
in C and D represent means ± SEM of culture duplicates of three to fi  ve 
mice/group from one representative experiment of the two shown in 
A and B. (E) Single cell analysis of IL-17 and IFN-γ–producing CD4+ T cells 
in anti–IL-10R–treated Hh+ WT and Hh+ IL-10–/– mice. MLN cells from 
uninfected (top) or 6-wk-infected anti–IL-10R–treated WT (bottom left) 
or 6-wk-infected IL-10–/– mice (bottom right) were cultured with SHelAg 
for 72 h. After an additional incubation for 18 h in medium, cells were 
stimulated with PMA and ionomycin in the presence of brefeldin A, and 
three-color staining for CD4, IL-17, and IFN-γ was performed. The FACS 
dot plots shown are gated on CD4+ cells and are representative of more 
than three experiments performed.JEM VOL. 203, October 30, 2006  2487
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Rag–/– transfer model also functions in intact Hh+ WT hosts, 
as treatment of these animals with anti–IL-10R, but not a 
control mAb, led to the development of typhlocolitis similar 
to that seen in Hh+ IL-10–/– mice (Figs. 1, A and B, and 2, 
A, B, F, and G). Uninfected WT mice given anti–IL-10R 
did not develop intestinal infl   ammation (not depicted), 
demonstrating that the endogenous fl  ora by itself was not 
suffi   cient to induce colitis, but that H. hepaticus was required 
for disease initiation.
In agreement with our earlier fi  ndings of a critical role for 
p40 in colitis induction (20, 21), Hh+ p40–/– mice treated with 
anti–IL-10R failed to develop typhlocolitis (Figs. 1, A and B, 
and 2, C and H). Importantly however, anti–IL-10R–treated 
Hh+ p35–/– mice, which lack the ability to produce IL-12, de-
veloped intestinal infl  ammation comparable to that seen in 
anti–IL-10R–treated Hh+ WT mice (Figs. 1, A and B, and 2, 
D and I). Collectively, these fi  ndings demonstrate that al-
though the IL-12p40 subunit is essential for colitis develop-
ment, IL-12 in itself is dispensable for disease pathogenesis.
To investigate the role of IFN-γ, mice defi  cient in this 
cytokine were infected with H. hepaticus and treated with 
anti–IL-10R. Although the degree of cecal infl  ammation 
was comparable to that observed in colitic Hh+ WT and 
p35–/– animals (Figs. 1 A and 2 E), IL-10R blockade led 
to only a mild infl  ammatory response in the colon of Hh+ 
IFN-γ–/– animals (Figs. 1 B and 2 J), suggesting a role for 
IFN-γ in exacerbating disease at this site. This conclusion 
was supported by similar fi  ndings in an adoptive transfer 
model (see below), emphasizing a role for IFN-γ in pro-
moting colonic infl  ammation.
H. hepaticus–specifi  c IFN-𝗄 and IL-17 responses 
are elevated in colitic mice
To examine H. hepaticus–specifi  c T cell cytokine responses, 
mesenteric lymph node (MLN) cells were stimulated in vitro 
with soluble H. hepaticus antigen (SHelAg) and levels of IFN-γ 
and IL-17 were measured. After bacterial antigen stimula-
tion, MLN cells from Hh+ IL-10–/– mice mounted a strong 
IFN-γ response and secreted substantial amounts of IL-17, 
whereas MLN cells from Hh+ WT mice given control mAb 
failed to produce these cytokines (Fig. 1, C and D). Similarly, 
no IFN-γ or IL-17 was detected in SHelAg-stimulated MLN 
cultures from control mAb–treated Hh+ p40–/–, p35–/–, or 
IFN-γ–/– mice. In contrast, MLN cells from anti–IL-10R–
treated Hh+ WT mice secreted elevated amounts of both 
IFN-γ and IL-17 in response to SHelAg (Fig. 1, C and D). 
Interestingly, a similar picture was seen for anti–IL-10R–
treated Hh+ p35–/– mice, with a signifi  cant IFN-γ response 
and markedly enhanced IL-17 levels after SHelAg stimula-
tion (Fig. 1, C and D). Importantly, although displaying 
  attenuated colonic infl  ammation, MLN cells from anti–IL-
10R–treated Hh+ IFN-γ–/– mice exhibited a strong SHelAg-
induced IL-17 response (Fig. 1 D). Intracellular cytokine 
staining of MLN cells from anti–IL-10R–treated Hh+ WT 
and Hh+ IL-10–/– mice demonstrated that SHelAg-induced 
IL-17 and IFN-γ were mainly produced by distinct popu-
lations of CD4+ cells, with a smaller fraction of cells stain-
ing positive for both cytokines (Fig. 1 E). In preliminary 
Figure 2.  Intestinal pathology in anti–IL-10R–treated Hh+ T cell–
suffi  cient mice. B6 WT, p40–/–, p35–/–, and IFN-γ–/– mice were infected 
with H. hepaticus and treated with control or anti–IL-10R mAb once a 
week for 4 wk. 1 wk after the last mAb administration, pathology was 
analyzed in the cecum (A–E) and ascending colon (F–J). Shown is the 
histology of representative cecal and colonic sections from the mice in 
Fig. 1 (A and B). (A and F) Hh+ WT plus control mAb, (B and G) Hh+ WT 
plus anti–IL-10R, (C and H) Hh+ p40–/– plus anti–IL-10R, (D and I) Hh+ 
p35–/– plus anti–IL-10R, and (E and J) Hh+ IFN-γ–/– plus anti–IL-10R. The 
tissue photomicrographs shown were scored as follows: A, 0; B, 5; C, 0; 
D, 6; E, 7; F, 0; G, 3; H, 0; I, 2; J, 0. Note that the scores in Fig. 1 represent 
a total score for the whole section and include cells infi  ltrating the serosa 
as well as crypt abscesses and ulcers, all of which are absent in the above 
photomicrographs. Hematoxylin and eosin staining. Bars, 50 μm.
Figure 3.  Cytokine mRNA levels in the colons of anti–IL-10R–
treated Hh+ WT mice. Colonic tissues from uninfected or 4-wk-infected 
WT mice treated with control mAb or anti–IL-10R were collected and pro-
cessed for real-time RT-PCR analysis of p19, p35, p40, IL-17A, IL-17F, and 
IFN-γ. Bars represent data from individual mice (two uninfected and four 
Hh+ mice per group) in one of the experiments shown in Fig. 1 (A and B). 
Error bars represent the range of fold difference in gene expression.2488  IL-23 MEDIATES BACTERIAL-INDUCED COLITIS | Kullberg et al.
experiments, anti–IL-10R–treated Hh+ IFN-γ–/– mice dem-
onstrated an increased frequency of IL-17+ CD4+ cells after 
SHelAg stimulation (1.8–4.7-fold increase compared with 
similarly treated WT mice; data from two independent ex-
periments). Collectively, these results indicate that although 
Th17 responses may be suffi   cient to induce severe cecal in-
fl  ammation, maximal infl  ammation in the colon also depends 
on IFN-γ.
To examine cytokine responses at the site of infl  amma-
tion, mRNA levels for p19, p35, p40, IL-17A, IL-17F, and 
IFN-γ were measured in colon samples from Hh+ WT mice 
given control or anti–IL-10R mAb. As shown in Fig. 3, both 
Hh+ groups showed an approximately twofold increase in 
p19 levels compared with uninfected controls. In contrast, 
p35 levels were slightly reduced in both Hh+ groups, whereas 
p40 levels were unchanged in control mAb–treated Hh+ WT 
mice but increased >20-fold in anti–IL-10R–treated Hh+ 
WT mice. Interestingly, mRNA levels for IL-17A, IL-17F, 
and IFN-γ were approximately 40-fold, ninefold, and 150-
fold higher in anti–IL-10R–treated compared with control 
mAb–treated Hh+ WT mice (Fig. 3).
Anti-p40 treatment prevents intestinal pathology 
in anti–IL-10R–treated Hh+ mice
To examine if the IL-12p40 subunit is also required for 
disease development in the absence of IL-12, p35–/– mice 
were infected with H. hepaticus and treated with anti–IL-
10R alone or anti–IL-10R plus anti-p40 mAb. As shown 
in Fig. 4 A, anti-p40 treatment completely abrogated both 
cecal and colonic infl  ammation in anti–IL-10R–treated Hh+ 
WT or p35–/– mice. In addition, anti-p40 treatment blocked 
SHelAg-induced IFN-γ and IL-17 secretion observed in 
MLN cultures from the same groups of Hh+ mice (Fig. 4, B 
and C). Importantly, anti-p40 treatment also prevented the 
cecal infl  ammation observed in Hh+ IFN-γ–/– mice given 
anti–IL-10R (Fig. 4 A), and this correlated with a complete 
loss of SHelAg-induced IL-17 production (Fig. 4 C). Collec-
tively, these fi  ndings confi  rmed a crucial role for p40 in the 
development of H. hepaticus–induced intestinal infl  ammation 
even in the absence of IL-12, and again indicated a correla-
tion between IL-17, IFN-γ, and pathology.
IL-12 is not required for the development 
of T cell–dependent colitis in Hh+ Rag–/– mice
In light of the shared p40 subunit between IL-12 and IL-23, 
we reasoned that the p40-dependent, but IL-12–independent 
induction of H. hepaticus–triggered colitis was likely to be 
  mediated by IL-23. As various cytokine-defi  cient Rag–/– 
  animals were available to us, we next turned to an adoptive 
transfer model of colitis using Rag–/– mice defi  cient in IL-12 
(p35Rag–/–), IL-23 (p19Rag–/–), or both IL-12 and IL-23 
(p40Rag–/–) to further elucidate the role of IL-23 in disease 
development. In this model, colitis is induced in an IL-10–
suffi   cient setting in Hh+ B6 or B10 Rag–/– recipients by trans-
fer of CD4+ T cells (22). We fi  rst confi  rmed a critical role for 
p40 in the adoptive transfer model, as Hh+ p40Rag–/– mice 
failed to develop typhlocolitis after transfer of WT CD4+ 
CD45RBhi cells (Fig. 5, A and B) or IL-10–/– CD4+ cells (not 
depicted). In contrast, Hh+ Rag–/– and p35Rag–/– mice devel-
oped severe typhlocolitis after reconstitution with the same T 
cell populations (Fig. 5, A and B, and not depicted). Impor-
tantly, anti-p40 treatment inhibited intestinal infl  ammation 
in T cell–reconstituted Hh+ Rag–/– and p35Rag–/– animals 
(Fig. 5, A and B), demonstrating a requirement for p40 but 
not IL-12 in disease induction also in this model. In con-
trast, anti–IFN-γ treatment had no eff  ect on cecal pathology 
(Fig. 5 A) but signifi  cantly reduced the infl  ammation in the 
Figure 4.  Anti-p40 mAb treatment prevents intestinal pathology 
in anti–IL-10R–treated Hh+ mice. B6 WT, p35–/–, and IFN-γ–/– mice 
were infected with H. hepaticus and treated with control, anti–IL-10R, or 
anti–IL-10R plus anti-p40 mAb once a week for 4 wk. 1 wk after the last 
mAb administration, pathology was analyzed in the cecum (A, black bars) 
and ascending colon (A, gray bars). Despite signifi  cant cecal pathology, 
anti–IL-10R–treated Hh+ IFN-γ–/– mice failed to develop infl  ammation in 
the colon. MLN cells were cultured with SHelAg, and IFN-γ (B) and IL-17 
(C) were measured in 72-h supernatants. No IFN-γ or IL-17 was detected 
from cells cultured in medium alone. Bars in A represent mean histol-
ogy scores ± SEM of four mice/group. Bars in B and C represent 
means ± SEM of culture duplicates of MLN cells pooled from the mice 
in A. nd, not detected.JEM VOL. 203, October 30, 2006  2489
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colon of the Hh+ Rag–/– and p35Rag–/– recipients (Fig. 5 B). 
Similarly, although WT and IFN-γ–/– CD4+ CD45RBhi 
cells induced a similar degree of cecal infl  ammation in Hh+ 
Rag–/– mice (Fig. 5 A), recipients of IFN-γ–/– CD4+ cells 
showed reduced infl  ammation in the colon (Fig. 5 B). These 
fi  ndings are consistent with the previously observed diff  er-
ence in disease severity in the cecum versus colon of Hh+ 
IFN-γ–/– mice treated with anti–IL-10R (Figs. 1, A and B, 
and 2, E and J), and further support an important role for 
T cell–derived IFN-γ in disease pathogenesis in the colon.
IL-23 is essential for the development of maximal colitis 
and intestinal proinfl  ammatory cytokine production
To directly assess the contribution of IL-23 in the develop-
ment of colitis in the H. hepaticus/Rag–/– transfer model, an 
additional series of experiments was performed that included 
p19Rag–/– recipients, which lack the ability to produce IL-23. 
As shown in Fig. 6 (A and B), CD4+ T cell–reconstituted 
Hh+ p19Rag–/– mice displayed attenuated intestinal infl  am-
mation compared with Rag–/– recipients, demonstrating a 
crucial role for IL-23 in disease pathogenesis. However, 
compared with disease-free Hh+ p40Rag–/– recipients, some 
residual intestinal infl  ammation was observed in T cell–re-
constituted Hh+ p19Rag–/– mice (Fig. 6, A and B). These 
data suggest that, although not absolutely required for intesti-
nal infl  ammation, IL-12 contributes to the mild intestinal in-
fl  ammation observed in the absence of IL-23. Nevertheless, 
of the two cytokines, IL-23 appears to be more important in 
the disease process, as the infl   ammation present in Hh+ 
p19Rag–/– recipients was signifi   cantly reduced compared 
with that observed in p35Rag–/– hosts (Fig. 6, A and B). Im-
portantly, fl   ow cytometric analysis revealed no signifi  cant 
diff   erence in CD4+ cell numbers in the spleens of Hh+ 
p19Rag–/– and p35Rag–/– recipients (not depicted), demon-
strating that the attenuated pathology in p19Rag–/– mice was 
not due to lower T cell reconstitution. Moreover, there was no 
correlation between degree of infl  ammation and H. hepaticus 
colonization levels, as all groups harbored similar concentra-
tions of H. hepaticus in their cecal contents (Fig. 6 C).
We next quantitated cytokines in colon homogenates 
from the diff  erent groups of T cell–reconstituted Hh+ Rag–/– 
mice. As shown in Fig. 6 (D–G), the absence of both IL-12 
and IL-23 led to abolished TNF-α, IFN-γ, MCP-1, and IL-6 
levels in colon homogenates of T cell–reconstituted Hh+ 
p40Rag–/– animals. IL-12–defi  cient Hh+ p35Rag–/– recipi-
ents showed similar or marginally decreased levels of proin-
fl  ammatory cytokines compared with Hh+ Rag–/– recipients. 
Finally, the absence of IL-23 in Hh+ p19Rag–/– mice led to a 
further reduction in proinfl  ammatory cytokine production 
(Fig. 6, D–G), emphasizing the crucial role for IL-23 in me-
diating this response.
DISCUSSION
Before the discovery of IL-23 and its recently documented 
role in autoimmune disorders (2–5), the common view in the 
fi  eld of Th1-mediated intestinal infl  ammation has been that 
IL-12, by initiating and maintaining Th1 responses, is crucial 
for disease pathogenesis. We here demonstrate that IL-23 and 
not IL-12 is essential for the induction of maximal bacterial-
induced T cell–dependent colitis. This conclusion is based on 
results from two complementary models of intestinal infl  am-
mation triggered by H. hepaticus. Using an established CD4+ 
T cell adoptive transfer model of colitis (22), we observed 
that although severe intestinal infl  ammation was still induced 
in IL-12–defi  cient (p35Rag–/–) recipients, selective ablation 
of IL-23 (p19Rag–/–) resulted in attenuation of disease. In ad-
dition, using a novel model of colitis involving anti–IL-10R 
treatment of Hh+ WT animals that circumvents the lympho-
penic environment of Rag–/– mice, we confi  rm an essential 
role for p40 and not IL-12 in intestinal infl  ammation also in 
immune competent hosts.
IL-23, which is produced by DCs and macrophages in re-
sponse to Toll-like receptor stimuli (23), may contribute to 
intestinal pathology in multiple ways. By inducing the pro-
duction of IL-1β, TNF, IL-12, and IFN-γ by cells of the 
Figure 5.  Hh+ Rag–/– and p35Rag–/–, but not p40Rag–/–, mice de-
velop intestinal infl  ammation after T cell reconstitution. Hh+ B6/B10 
Rag–/–, p40Rag–/–, and p35Rag–/– mice were inoculated i.v. with 3 × 105 
CD4+ CD45RBhi cells from uninfected WT or IFN-γ–/– animals as indicated. 
Separate groups of Hh+ Rag–/– and p35Rag–/– recipients of WT CD4+ 
CD45RBhi cells were also treated with anti-p40 or anti–IFN-γ on days 0, 7, 
14, and 21 of cell transfer. Pathology in the cecum (A) and ascending 
colon (B) was analyzed 4 wk after cell transfer. Infected mice receiving no 
cells were included as controls (○). Data are pooled from two separate 
experiments and show histology scores from individual mice, with the 
horizontal line indicating the average for each group.2490  IL-23 MEDIATES BACTERIAL-INDUCED COLITIS | Kullberg et al.
  innate immune system (3, 24), IL-23 can directly participate 
in triggering a proinfl  ammatory cytokine cascade. A key role for 
IL-23 in driving innate intestinal pathology was indeed ob-
served in a complementary study by Hue et al. (25), in which 
depletion of IL-23p19 attenuated the T cell–independent 
typhlocolitis that develops in Hh+ 129SvEvRag–/– mice. IL-23 
is also known to amplify and/or stabilize Th17 cells (26), 
which through their secretion of IL-17 induce myeloid and 
endothelial cell expression of proinfl  ammatory cytokines (IL-1, 
IL-6, IL-8, TNF-α, and GM-CSF) and chemokines (3, 10, 
27). In addition to our fi  ndings of increased IL-17 responses 
in colitic mice, several of the eff  ects we observed in our T 
cell–dependent model of colitis may be interpreted in terms 
of Th17 function and subsequent recruitment of infl  amma-
tory cells to the intestine. Thus, both cecal infl  ammation and 
SHelAg-specifi  c IL-17 responses observed in anti–IL-10R–
treated Hh+ IFN-γ–/– mice were inhibited by co-administra-
tion of anti-p40 mAb. Moreover, IFN-γ–/– CD4+ CD45RBhi 
cells were equivalent to their WT counterparts in terms of 
inducing cecal infl  ammation (Fig. 5 A), and these cells were 
also pathogenic in an IL-12–defi  cient setting in p35Rag–/– 
hosts (not depicted). Collectively, these fi  ndings argue for an 
IL-23–driven IFN-γ–independent component in disease 
pathogenesis, a conclusion in agreement with the pathogenic 
role of Th17 cells in EAE and CIA (3–5, 28).
Th17 cells represent a unique linage distinct from the 
Th1 and Th2 subsets, as their development is inhibited by 
IFN-γ and IL-4 and is independent of STAT4, STAT6, 
STAT1, and T-bet (8, 9). Three recent reports have now es-
tablished that TGF-β, in the presence of IL-6, is critical for 
the development of Th17 cells, whereas IL-23 appears dis-
pensable for Th17 commitment and initial IL-17 production 
(29–31). IL-23 is, however, clearly essential for a fully eff  ec-
tive Th17 response in vivo, as exemplifi  ed in EAE and CIA 
as well as in various infections with extracellular bacteria 
(e.g., Klebsiella pneumoniae and Citrobacter rodentium; references 
3–5, 28, 30, and 32). Our fi  ndings of up-regulated IL-17A 
(and to a lesser extent IL-17F) mRNA levels in the absence 
of signifi  cant induction of IL-23p19 or p40 in colonic tissues 
of Hh+ control mAb–treated WT mice that show no colitis 
(Fig. 3) support these conclusions. The mechanism behind 
the IL-23 dependency for eff  ective Th17 responses is still 
Figure 6.  IL-23 is essential for the development of maximal colitis 
and intestinal proinfl  ammatory cytokine production. Hh+ B6 Rag–/–, 
p40Rag–/–, p35Rag–/–, and p19Rag–/– mice were inoculated i.p. with 4 × 105 
CD4+ CD45RBhi cells from uninfected WT animals as indicated. Pathology 
in the cecum (A) and ascending colon (B) was analyzed 4 wk later. Data 
are pooled from two separate experiments and show histology scores 
from individual mice, with the horizontal line indicating the average for 
each group. (C) H. hepaticus colonization levels were quantifi  ed using 
real-time PCR. Bars represent means ± SEM of H. hepaticus DNA levels 
from the individual mice shown in A and B. (D–G) Cytokine levels in colon 
homogenates were determined by cytometric bead assay and normalized 
to the total amount of protein in each sample. Shown are TNF-α (D), IFN-γ 
(E), MCP-1 (F), and IL-6 (G). Data are pooled from the two experiments 
shown in A and B assayed as individual mice in experiment 1 and as two 
pools of three mice/group in experiment 2. The dotted line represents 
cytokine levels in unreconstituted Hh+ Rag–/– mice.JEM VOL. 203, October 30, 2006  2491
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unknown. As IL-23R expression is up-regulated by TGF-β, 
thus downstream of signals that initiate Th17 diff  erentiation 
(8, 30), one possibility is that IL-23 stabilizes and/or main-
tains Th17 cells, analogous to the role of IL-12 in stabilizing 
Th1 cells after their expression of IL-12Rβ2 (26). So far, the 
role of IL-10 in Th17 development has not been carefully 
examined. To the best of our knowledge, the results pre-
sented here are the fi  rst to demonstrate an inhibitory role for 
IL-10 in the development of IL-17–producing CD4+ T cells 
in vivo, as anti–IL-10R treatment of Hh+ WT mice led to 
markedly increased H. hepaticus antigen-specifi  c IL-17 re-
sponses. The mechanism by which IL-10 exerts its down-
regulatory eff  ect on IL-17 production is currently unknown 
but was shown to be independent of IL-12 and IFN-γ, as 
anti–IL-10R–treated Hh+ p35–/– and IFN-γ–/– mice also dis-
played increased IL-17 responses. One possibility is that IL-
10 inhibits IL-23 secretion by cells of the innate immune 
system, thereby limiting the amount of IL-23 available to 
maintain Th17 cells. Alternatively, IL-10 might have a 
down-regulatory eff   ect on IL-23R expression on CD4+ 
cells, as has been described for bone marrow–derived macro-
phages (6), thereby rendering these cells less responsive to 
IL-23. In the study by Veldhoen et al. (29), IL-17–secreting 
T cells were generated in vitro in cocultures of naive CD4+ 
cells with naturally occurring CD25+ CD4+ T regulatory 
cells in the presence of Toll-like receptor stimuli. In contrast 
to our fi  ndings, blocking IL-10 in this model did not result 
in an increased frequency of IL-17–producing T cells (29). 
However, as the percentage of IFN-γ–secreting CD4+ cells 
increased in the same cultures (29), a possible inhibitory ef-
fect of IFN-γ on the development of IL-17–producing cells 
cannot be excluded.
Although, as shown in this study, IL-23 and not IL-12 is 
essential for the development of maximal pathology in T 
cell–dependent bacterial-induced intestinal infl  ammation, 
there are some diff  erences between our model and the EAE 
and CIA models in regard to the contribution of IL-12 and 
IFN-γ to disease pathogenesis. Thus, in the sole absence of 
IL-12 (p35–/– mice), disease severity was enhanced in EAE 
and CIA (3, 5), whereas for colitis induced by anti–IL-10R 
treatment of Hh+ p35–/– mice or by T cell transfer into Hh+ 
p35Rag–/– recipients, this was not the case. One explanation 
for this diff  erence could be that IL-17–secreting CD4+ T 
cells are the major pathogenic population in the former two 
models, with IL-12–driven IFN-γ suppressing the genera-
tion of IL-17+ Th cells (8, 9, 30), whereas in the colitis set-
ting, both IL-17 and IFN-γ contribute to disease pathogenesis. 
Indeed, loss of IFN-γ or the IFN-γ receptor was associated 
with an increased disease severity in both EAE and CIA 
(33–37), whereas as shown here, IFN-γ defi  ciency led to largely 
unaff  ected cecal pathology but reduced colonic infl  amma-
tion. These fi  ndings indicate that IFN-γ enhances rather than 
suppresses infl  ammation in the intestinal tract, a conclusion 
supported by previous studies demonstrating that anti–IFN-γ 
treatment prevents the development of colitis (20, 38, 39). 
Yen et al. (40) have recently reported that IL-23 is required 
for the development of spontaneous enterocolitis in IL-10–/– 
animals, a fi  nding attributed to IL-17 and IL-6 based on mAb 
neutralization studies in an adoptive transfer model. Impor-
tantly, neutralization of IL-17 or IL-6 alone did not signifi  -
cantly reduce pathology, and although combined treatment 
attenuated the colitis, it did not completely inhibit the in-
fl  ammation (40). Based on our fi  ndings, we hypothesize that 
additional pathogenic eff   ector mechanisms synergize with 
IL-17/IL-6 to induce severe intestinal infl  ammation. In par-
ticular, our results highlight that although not absolutely re-
quired for cecal disease, IFN-γ plays a synergistic role in the 
induction of colonic infl  ammation. The reason for the diff  er-
ence in cytokine requirements to induce maximal pathology 
in the cecum versus the colon is currently unclear, but it may 
refl  ect distinct levels of bacterial colonization (41) leading to 
diff  erent induction of cytokines and/or chemokines.
Interestingly, this study revealed a role for H. hepaticus–
induced IL-12–independent, but p40-dependent IFN-γ in 
intestinal pathology. Whether the molecular mechanism be-
hind this fi  nding involves p40 acting alone, as a homodimer, 
or in association with other chains remains unknown. How-
ever, it is possible that these observations refl  ect the involve-
ment of IL-23 in triggering H. hepaticus–induced CD4+ 
IFN-γ production in IL-12–defi  cient mice. This conclusion 
is supported by recent fi  ndings from the Mycobacterium tuber-
culosis model in which antigen-specifi  c IFN-γ+ CD4+ cells 
were shown to develop in infected p35–/– mice via a p19-
  dependent mechanism, contributing to the prolonged survival 
of these hosts compared with infected p40–/– animals (42, 
43). The co-appearance of antigen-reactive IFN-γ+ CD4+ 
and IL-17+ CD4+ cells in p35–/– mice in both the M. tuberculosis 
(43) and H. hepaticus models suggests that the IL-23–induced 
IFN-γ detected in these animals may not be suffi   cient to 
block the generation of IL-17–secreting CD4+ cells. Based 
on the data presented here, we instead propose a modifi  ed 
model in which IFN-γ may have either inhibitory or syner-
gistic eff  ects on Th17 development and/or eff  ector function. 
Thus, in settings with large amounts of the cytokine, IL-12–
induced IFN-γ exerts negative eff  ects on Th17 development, 
as described by Harrington et al. (8), Park et al. (9), and 
Mangan et al. (30), and as exemplifi  ed by Hh+ IL-10–/– mice 
that mount markedly enhanced IFN-γ but reduced IL-17 
levels compared with anti–IL-10R–treated Hh+ p35–/– mice 
(Fig. 1, C and D). However, in settings with no IL-12, lower 
levels of IL-23–dependent IFN-γ (or IFN-γ induced by an-
other p40-dependent mechanism) act together with IL-17 to 
enhance intestinal infl  ammation (Fig. 1, B–D, compare p35–/– 
with IFN-γ–/– mice). It is important to point out that al-
though IL-12 is dispensable for colitis induction, this cytokine 
may still contribute to intestinal pathology, as shown in the T 
cell transfer experiments in which p19Rag–/– recipients dis-
played a signifi  cantly higher level of intestinal infl  ammation 
compared with p40Rag–/– recipients (Fig. 6, A and B). Be-
sides the role of IL-12 in Th1 development, the IL-12p40 
subunit by itself (possibly as a homodimer) may also  contribute 
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(44–46) and its recently described role in DC migration and 
subsequent T cell priming (47).
Collectively, the data presented in this study demonstrate 
that IL-23 and not IL-12 is essential for the pathogenesis of 
T cell–dependent bacterial-induced intestinal infl  ammation. 
Although IL-23 may constitute a potential therapeutic target 
for IBD, our fi  ndings further support a model in which 
  multiple factors downstream of IL-23 (e.g., IL-17, IL-6, and 
IFN-γ) may contribute to intestinal infl  ammation and to-
gether synergize to induce maximal pathology. Further 
  identifi   cation and characterization of these downstream 
components and mechanisms should help dissect the immuno-
logical pathways involved in IBD, and should aid in the de-
velopment of new therapeutic treatments for patients with 
these chronic infl  ammatory diseases of the intestinal tract.
MATERIALS AND METHODS
Experimental animals and infections. Female or male specifi  c patho-
gen-free C57BL/6 (B6) WT, B6 p40–/–, B6 IFN-γ–/–, C57BL/10 (B10) 
IL-10–/–, B10 Rag-2–/– (Taconic Farms), and B6 p35–/– mice (The Jackson 
Laboratory) were used at 6–10 wk of age. p40Rag–/– and p35Rag–/– animals 
were generated by crossing the above mentioned single cytokine-defi  cient 
mice, and the progeny were intercrossed to generate double-defi  cient off  -
spring. For Fig. 6, Rag–/–, p40Rag–/–, p35Rag–/–, and p19Rag–/– animals on 
the B6 background were used (25). The animals used tested negative for an-
tibodies to specifi  c murine viruses and were free of Helicobacter species as as-
sessed by PCR. Animals were housed in sterile microisolator cages at the 
National Institute of Allergy and Infectious Disease (NIAID) animal facility 
under a study proposal approved by the NIAID Animal Care and Use Com-
mittee or in accredited animal facilities at the University of Oxford accord-
ing to the UK Scientifi  c Procedures Act 1986.
Mice were inoculated intragastrically with 0.5 ml of an H. hepaticus 
  suspension (NCI-Frederick isolate 1A [reference 48] isolated from the 
same mouse colony as isolate Hh-1; American Type Culture Collection 
51449 [reference 49]) prepared to a McFarland turbidity standard of 
1.0 in PBS representing 2.45 × 109 CFU/ml. For the experiments shown 
in Fig. 6, three doses of 5 × 107–2 × 108 CFU were given to mice on 
days 0, 2, and 4. Age- and sex-matched uninfected animals were   included 
as controls.
In vivo mAb treatment. To analyze the eff  ect of in vivo neutralization 
of IL-10R, IL-12/IL-23 p40, or IFN-γ, mice were treated i.p. with 1 mg 
per injection of mAb 1B1.3a (anti–IL-10R), C17.8 (anti-p40), XMG-6 
(anti–IFN-γ), or a control mAb, GL113 (anti–β-galactosidase), in 0.5 ml 
PBS on days 0, 7, 14, and 21 of H. hepaticus infection or cell transfer (for T 
cell–suffi   cient mice and Rag–/– recipients, respectively). 1 wk after the last 
mAb injection, mice were killed, MLNs were collected for in vitro culture, 
and intestinal tissues were collected in Bouin’s fi  xative for histology and in 
RNA-later (Ambion) for real-time PCR analysis.
Cell preparations and purifi  cations. Single cell suspensions were pre-
pared from MLNs, and cells were resuspended in complete tissue culture 
medium (22). For purifi  cation of CD4+ CD45RBhi cells, MLN cells from 
naive WT or IFN-γ–/– mice were stained with anti–CD4-PE (clone RM4-5) 
or anti–CD4-CyChrome (RM4-5) and anti–CD45RB-FITC (16A; all from 
BD Biosciences) and sorted on a FACSVantage or a FACStarPlus (Becton 
Dickinson), gating on  50% of the brightest CD4+ cells. For the experi-
ment shown in Fig. 6, splenic CD4+ CD45RBhi cells from WT mice were 
used. The sorted CD4+ CD45RBhi cells were ≥99% pure.
Cell cultures and cytokine assays. MLN cells (5 × 106/ml) pooled from 
three to fi  ve mice/group were cultured in medium alone or with 5 μg/ml 
of SHelAg in 96-well fl  at-bottomed plates (0.2 ml/well) at 37°C and 5% 
CO2, and supernatants were collected after 72 h. SHelAg was prepared as 
described previously (20), boiled for 5 min (22), and stored at –40°C until 
use. IFN-γ and IL-17 were measured by ELISA using mAb from BD Bio-
sciences and R&D Systems, respectively.
Intracellular cytokine staining. Analyses of intracellular cytokine expres-
sion were performed on cells from the same SHelAg-stimulated MLN cul-
tures used for cytokine secretion assays as described previously (22, 50). In 
brief, cells were incubated for an additional 18 h in fresh medium added to 
replace the culture supernatant collected at 72 h. Thereafter, cells were stim-
ulated with 10 ng/ml PMA and 1 μg/ml ionomycin (both from Sigma-Aldrich) 
for 4.5 h with the addition of 10 μg/ml brefeldin A (Sigma-Aldrich) during 
the last 2 h. Intracellular staining was then performed as described previously 
(22, 50) using anti–IL-17–PE (TC11-18H10.1) and anti–IFN-γ–FITC 
(XMG1.2; both from BD Biosciences). Cell fl  uorescence was measured 
  using a FACSCalibur (Becton Dickinson), and data were analyzed using 
CELLQuest software (Becton Dickinson).
Cell transfers to Rag–/– mice. Unless otherwise indicated, CD4+ 
CD45RBhi cells (3 × 105/mouse) were transferred i.v. to naive or 2–4-d-
  infected Rag–/– mice. Mice were killed 4 wk after cell transfer, and inte-
stinal tissues were collected for histologic analysis and measurements 
of cytokines.
Pathology. Intestinal tissues were processed and infl  ammation in the cecum 
(typhlitis) and ascending colon was scored in a blinded fashion by the same 
pathologist (A.W. Cheever) on a scale from 0 to 20 as described previously 
(22). In brief, a longitudinal section of the entire cecum was made together 
with a cross section of the ascending colon  1 cm from the cecum, and a 
total score for the whole section was assigned based on a 0–4+ scoring sys-
tem for diff  erent features with emphasis on the number of infi  ltrating cells 
for the lamina propria, the submucosa, and the serosa. In addition, crypt 
  abscesses and ulcers were each given a score from 0 to 4. A total score was 
calculated by adding the individual scores.
Real-time RT-PCR for detection of cytokine mRNA. Because, in 
general, the degree of infl  ammation in the colon proportionally refl  ects that 
observed in the cecum, the colon was chosen for real-time RT-PCR an-
alyses (and cytokine protein determinations; see below) to avoid the lym-
phocyte patches present irregularly throughout the cecum while preserving 
the intact cecum for histological examination. Total RNA was isolated from 
polytron-homogenized colonic tissue ( 3 mm of ascending colon distal of 
the piece used for histology) using the RNeasy mini kit, including a   DNase 
treatment step as recommended by the manufacturer (QIAGEN). 6–9 μg 
RNA was reverse transcribed using Superscript III reverse transcriptase 
and oligo-dT primers (both from Invitrogen). cDNA was amplifi  ed using 
TaqMan reagents and a Chromo4 detection system (MJ Research). Cyto-
kine expression levels for each individual sample (run in triplicates) were 
normalized to HPRT using ∆Ct calculations. Mean relative cytokine ex-
pression levels between control and experimental groups (n = 2–4 mice/
group) were determined using the 2-∆∆Ct formula. Specifi  c primer pairs and 
FAM/TAMARA- or VIC/TAMARA-labeled probes were as follows: 
HPRT: primers 5′-G  A  C  C  G  G  T  C  C  C  G  T  C  A  T  G  C  -3′, 5′-T  C  A  T  A  A  C  C  T  G-
G  T  T  C  A  T  C  A  T  C  G  C  -3′, probe 5′-A  C  C  C  G  C  A  G  T  C  C  C  A  G  C  G  T  C  G  T  C  -3′; 
IL-23p19: primers 5′-A  G  C  G  G  G  A  C  A  T  A  T  G  A  A  T  C  T  A  C  T  A  A  G  A  G  A  -3′, 
5′-G  T  C  C  T  A  G  T  A  G  G  G  A  G  G  T  G  T  G  A  A  G  T  T  G  -3′, probe 5′-C  C  A  G  T  T  C  T-
  G  C  T  T  G  C  A  A  A  G  G  A  T  C  C  G  C  -3′; IL-12p35: primers 5′-T  A  C  T  A  G  A  G  A-
  G  A  C  T  T  C  T  T  C  C  A  C  A  A  C  A  A  G  A  G  -3′, 5′-T  C  T  G  G  T  A  C  A  T  C  T  T  C  A  A  G  T-
  C  C  T  C  A  T  A  G  A  -3′, probe 5′-A  G  A  C  G  T  C  T  T  T  G  A  T  G  A  T  G  A  C  C  C  T  G  T  G  -
C  C  T  -3′; IL-12p40: primers 5′-G  A  C  C  A  T  C  A  C  T  G  T  C  A  A  A  G  A  G  T  T  T  C  T-
A  G  A  T  -3′, 5′-A  G  G  A  A  A  G  T  C  T  T  G  T  T  T  T  T  G  A  A  A  T  T  T  T  T  T  A  A  -3′, probe 
5′-C  C  A  C  T  C  A  C  A  T  C  T  G  C  T  G  C  T  C  C  A  C  A  A  G  A  A  G  -3′; IL-17A: primers 
5′-G  C  T  C  C  A  G  A  A  G  G  C  C  C  T  C  A  G  -3′, 5′-C  T  T  T  C  C  C  T  C  C  G  C  A  T  T  G  A-
  C  A  -3′, probe 5′-A  C  C  T  C  A  A  C  C  G  T  T  C  C  A  C  G  T  C  A  C  C  C  T  G  -3′; IL-17F: JEM VOL. 203, October 30, 2006  2493
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primers 5′-A  G  G  G  C  A  T  T  T  C  T  G  T  C  C  C  A  C  G  T  G  A  A  T  -3′, 5′-G  C  A  T  T  G  A  -
T  G  C  A  G  C  C  T  G  A  G  T  G  T  C  T  -3′, probe 5′-C  A  T  G  G  G  A  T  T  A  C  A  A  C  A  T  C-
A  C  T  C  G  A  G  A  C  C  C  -3′; and IFN-γ:   primers 5′-G  G  A  T  G  C  A  T  T  C  A  T  G  A-
G  T  A  T  T  G  C  -3′, 5′-G  C  T  T  C  C  T  G  A  G  G  C  T  G  G  A  T  T  C  -3′; probe 5′-T  T  T  -
G  A  G  G  T  C  A  A  C  A  A  C  C  C  A  C  A  G  G  T  C  C  A  -3′.
Cytokine protein determinations in colon homogenates. To   measure 
cytokines at the protein level in the intestine, colonic tissues were snap 
  frozen and then homogenized in PBS containing a cocktail of protease 
  inhibitors (Protease Inhibitor Cocktail Tablets; Roche) using a tissue poly-
tron. After centrifugation at 10,000 g to pellet debris, levels of TNF-α, 
IFN-γ, MCP-1, and IL-6 were measured in supernatants using the cyto-
metric bead assay (BD Biosciences). Cytokine amounts were normalized to 
the total amount of protein in each sample, as measured by Bradford assay 
(Bio-Rad Laboratories).
Quantitation of H. hepaticus using real-time PCR. DNA was purifi  ed from 
cecal contents of Hh+ mice using the DNA Stool kit (QIAGEN). H. hepaticus 
DNA was quantifi   ed as described previously (41, 51) using a real-time 
  quantitative PCR method based on the cdtB gene, performed with a Chromo4 
  detection system. Standard curves were constructed using H. hepaticus DNA 
that was purifi  ed from bacterial cultures using the DNeasy kit (QIAGEN).
Statistical analysis. Colitis scores were compared using the nonparametric 
Mann-Whitney U test. Cytokine data and H. hepaticus colonization levels 
were analyzed by Student’s unpaired two-tailed t test. Diff  erences were con-
sidered statistically signifi  cant with P < 0.05.
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